Crispr Therapeutics shares tumble after significant earnings miss
Investing.com -- Shares of Videndum plummeted 38% as the company confirmed its FY24F results were in line with previous guidance but raised flags about its financial covenants.
The update, which was released today, revealed that Videndum has not met the terms for its March 2025 covenant test and is in ongoing discussions with lending banks for an amendment or waiver.
The company also reported that it has begun additional restructuring activities, including relocating production facilities from the UK to Italy, as part of its operational efficiency program. This move is expected to increase FY25F cost savings to £15m, up from the previously targeted £10m.
However, costs associated with the restructuring have climbed to approximately £15m, with £3m incurred in the last fiscal year.
Despite these challenges, management remains optimistic, citing gradual improvements in the market, particularly in the Cine and Broadcast sectors. They anticipate this will translate into stronger order momentum starting from March 2025.
While not expecting a significant surge in orders, management is confident in the improving sales trends and believes they are building a strong business foundation for the future.
Jefferies, a financial services company, provided a cautious outlook on the situation: "While mgmt comments on the group’s banking syndicate being supportive, we expect the market will want greater comfort on the Mar-25 test before giving mgmt the benefit of the doubt."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.